Detalhe da pesquisa
1.
Enhancing global access to cancer medicines.
CA Cancer J Clin
; 70(2): 105-124, 2020 03.
Artigo
Inglês
| MEDLINE | ID: mdl-32068901
2.
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
Lancet
; 403(10437): 1649-1659, 2024 Apr 27.
Artigo
Inglês
| MEDLINE | ID: mdl-38582092
3.
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
N Engl J Med
; 387(3): 217-226, 2022 07 21.
Artigo
Inglês
| MEDLINE | ID: mdl-35857659
4.
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
N Engl J Med
; 386(6): 556-567, 2022 02 10.
Artigo
Inglês
| MEDLINE | ID: mdl-35139274
5.
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
N Engl J Med
; 387(1): 9-20, 2022 07 07.
Artigo
Inglês
| MEDLINE | ID: mdl-35665782
6.
Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom.
Br J Cancer
; 2024 Apr 24.
Artigo
Inglês
| MEDLINE | ID: mdl-38658782
7.
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
Lancet
; 402(10411): 1423-1433, 2023 10 21.
Artigo
Inglês
| MEDLINE | ID: mdl-37633306
8.
Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial.
Oncologist
; 2024 May 15.
Artigo
Inglês
| MEDLINE | ID: mdl-38748596
9.
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
N Engl J Med
; 384(16): 1529-1541, 2021 04 22.
Artigo
Inglês
| MEDLINE | ID: mdl-33882206
10.
A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative).
Future Oncol
; 20(11): 635-651, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38270051
11.
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease.
Breast Cancer Res
; 25(1): 67, 2023 06 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37308971
12.
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial.
Oncologist
; 28(1): 23-32, 2023 01 18.
Artigo
Inglês
| MEDLINE | ID: mdl-36239405
13.
Pembrolizumab for Early Triple-Negative Breast Cancer.
N Engl J Med
; 382(9): 810-821, 2020 02 27.
Artigo
Inglês
| MEDLINE | ID: mdl-32101663
14.
Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study.
Breast Cancer Res Treat
; 199(1): 35-46, 2023 May.
Artigo
Inglês
| MEDLINE | ID: mdl-36859649
15.
Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis.
BMC Cancer
; 23(1): 792, 2023 Aug 23.
Artigo
Inglês
| MEDLINE | ID: mdl-37612624
16.
TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.
Future Oncol
; 19(35): 2349-2359, 2023 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-37526149
17.
Emerging strategies for TNBC with early clinical data: new chemoimmunotherapy strategies.
Breast Cancer Res Treat
; 193(1): 21-35, 2022 May.
Artigo
Inglês
| MEDLINE | ID: mdl-35235095
18.
Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study.
Future Oncol
; 18(33): 3677-3688, 2022 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-36300423
19.
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer.
Future Oncol
; 18(32): 3563-3572, 2022 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-36382554
20.
Nickel release from metal items in contact with skin: a comparison of methods and practical implications for regulation in Europe.
J Environ Sci Health A Tox Hazard Subst Environ Eng
; 57(1): 45-51, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-34983324